{"commentary":{"count":27,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":13,"podcast":10,"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05120349\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ADAURA2","nct_id":"NCT05120349","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=adaura2-nct05120349. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"ADAURA2","arms":[{"description":"Osimertinib 80mg, orally, once daily (Dose may be reduced to 40 mg once daily if required at the discretion of the investigator)","label":"Osimertinib","type":"EXPERIMENTAL"},{"description":"Matching placebo for osimertinib, orally, once daily","label":"Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2032-11-01","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":390,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Osimertinib","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"last_update":"2026-07-06","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Participants With EGFR Mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, Following Complete Tumour Resection","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-08-02","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease-Free Survival (DFS) in high-risk stratum","timeFrame":"From date of randomisation up to approximately 10 years"}],"references":[{"citation":"Murat-Onana ML, Ramalingam SS, Janne PA, Gray JE, Ahn MJ, John T, Yatabe Y, Huang X, Rukazenkov Y, Javey M, Brown H, Li-Sucholeiki X. EGFR mutation testing across the osimertinib clinical program. Lung Cancer. 2025 Jun;204:108549. doi: 10.1016/j.lungcan.2025.108549. Epub 2025 Apr 18.","pmid":"40311309","type":"DERIVED"}],"start_date":{"date":"2022-02-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection","url":"https://clinicaltrials.gov/study/NCT05120349"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/adaura2-nct05120349"}